Protein News: Breaking Protein News, Comments and Articles. - Page: 2

Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency

PHILADELPHIA, May 22, 2013 /PRNewswire/ -- Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN©-C (Alpha1-Proteinase Inhibitor [Human]) increased levels of the alpha1 protein in patients with alpha1antitrypsin (AAT) deficiency to levels that are considered within the normal range for healthy individu...

A1-PI treatment slows progression of emphysema in patients with AATD

Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitryps...

Merck's Novel Immunotherapy Drug Receives 'Breakthrough Therapy Designation'

By The Swiss Trader:In April the global health care giant Merck & Co. (MRK), received "breakthrough therapy designation" from the U.S. Food and Drug Administration (FDA) for its investigational antibody therapy, lambrolizumab, a drug that treats patients with advanced melanoma. Lambrolizumab, which targets Programmed Cell Death protein (PD-1), disrupts the action of the immune checkpoint prote...

Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye

SOUTH SAN FRANCISCO, Calif., May 22, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a wholly-owned topical ophthalmic formulation of a JAK/SYK inhibitor, R348, being developed by Rigel as a treatment for dry eye disease.  The other two programs are aimed at oncology targets and are...

Omeros to Present at Two Upcoming Conferences

SEATTLE, May 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences: 38t...

How Many Binding Pockets Are There?

Just how many different small-molecule binding sites are there? That's the subject of this new paper in PNAS, from Jeffrey Skolnick and Mu Gao at Georgia Tech, which several people have sent along to me in the last couple of days. This question has...

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

BOTHELL, Wash. and VANCOUVER, British Columbia, May 22, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a leader in the development of novel therapeutics to target mechanisms of treatment resistance in cancer, today announced that four trials of its investigational compounds, custirsen and OGX-427, will be presented as "Trials in Progress" posters at the 49th Annual Meeti...

Rice University computational study tracks regulatory mechanisms of E. coli cells

Environment is not the only factor in shaping regulatory patterns -- and it might not even be the primary factor, according to a new Rice University study that looks at how cells' protein networks relate to a bacteria's genome.

Replenishment of GDF11 Reverses Cardiac Hypertrophy in Aging Animals

Experimental data collected by a team of cardiovascular disease researchers identified the decline in levels of the blood-borne protein...

Emory University researchers identify a protein that stimulates orphan receptors in the brain

Researchers at Emory University have identified a protein that stimulates a pair of "orphan receptors" found in the brain, solving a long-standing biological puzzle and possibly leading to future treatments for neurological diseases.

Global Protein and Antibody Engineering Market Research Report Submitted by Transparency Market Research

Albany, NY, May 22, 2013 --(PR.com)-- Antibodies and proteins developed with new and advantageous functions and properties are known as engineering of proteins and antibodies. Protein engineering can be defined as a process of developing valuable proteins and modification of antibodies to increase similarity and is called antibody engineering. Antibody and protein engineering is used in curing i...

[Comment] From mice to man: chloride transport in leukoencephalopathy

In The Lancet Neurology, Christel Depienne and colleagues show that mutations in CLCN2—the gene encoding the chloride channel ClC-2—underlie a specific form of human leukoencephalopathy. This important work confirms in human beings what was previ...

Identification Of Molecular Trigger For Alzheimer's Disease

Researchers have pinpointed a catalytic trigger for the onset of Alzheimer's disease - when the fundamental structure of a protein molecule changes to cause a chain reaction that leads to the death of neurons in the brain. For the first time, scienti...

Drug Side Effects May Be Inevitable

A new study of both computer-created and natural proteins suggests that the number of unique pockets - sites where small molecule pharmaceutical compounds can bind to proteins - is surprisingly small, meaning drug side effects may be impossible to av...

Study details genes that control whether tumors adapt or die when faced with p53 activating drugs

(University of Colorado Denver) When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die -- the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live e...

Taming suspect gene reverses schizophrenia-like abnormalities in mice

(NIH/National Institute of Mental Health) Scientists have reversed behavioral and brain abnormalities in adult mice that resemble some features of schizophrenia, by restoring normal expression to a suspect gene that is over-expressed in humans with t...

Acne treatment: Natural substance-based formula is more effective than artificial compounds

(University of Granada) The principle ingredient in the new formula -- patented through the Office for the Transfer of Research Results -- is a circular-structured, 70 amino acid protein known as AS-48.

Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases

RICHMOND, Calif., May 20, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform (IVPRP) to produce therapeutically relevant levels of Factor VIII in a mouse model.  Sangamo has partnered with Shire AG (LSE: SHP, NASDAQ: SHPG)...

Recruitment of arfaptins to the trans-Golgi network by PI(4)P and their involvement in cargo export

Recruitment of arfaptins to the trans-Golgi network by PI(4)P and their involvement in cargo exportArfaptins, BAR domain-containing proteins, bind PI(4)P at the Golgi in a protein kinase D-dependent manner to regulate the biogenesis of secretory stor...

In situ magnetic separation of antibody fragments from Escherichia coli in complex media

Background: In situ magnetic separation (ISMS) has emerged as a powerful tool to overcome process constraints such as product degradation or inhibition of target production. In the present work, an integrated ISMS process was established for the prod...

Minus environment, patterns still emerge

Environment is not the only factor in shaping regulatory patterns -- and it might not even be the primary factor, according to a new Rice University study that looks at how cells' protein networks relate to a bacteria's genome. read more

A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million

Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its plat...

Changing Cancer's Environment To Halt Its Spread

BOSTON, May 21, 2013 /PRNewswire-USNewswire/ -- By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer. The findings suggest that a prosaposin-based drug could po...

Biodesix to Announce Results of VeriStrat® Biomarker Study

Independent Phase III Data to Be Presented at the 2013 ASCO Annual Meeting Biodesix, Inc., announced that final results of the first completed biomarker-stratified, validation study in oncology will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31st – June 4th, 2013. The Randomized Pr...

Biosilo Premieres New Superfood Snack “Veggie PoppersTM” at Sweets and Snacks Expo 2013

Tasty, 100% All Natural, Non-GMO Snack Introduces “Fresh Snacking for a Better You” Biosilo Foods, Inc., creator of the popular gaming snack Gamer Grub®, continues to redefine snack innovation with the premiere of the tasty superfood snack